Notify me when Ridgeback Capital Investments L.P. files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | Common Stock, par value $0.001 per share | 0.6% | $373,600 | 359,231 | Ridgeback Capital Investments L.P. | 31 Dec 2024 | ||
| LENZ | Lenz Therapeutics, Inc. | Common Stock, par value $0.00001 per share | 0% | $0 | 0 | Ridgeback Capital Investments L.P. | 31 Dec 2025 | ||
| ITOS | iTeos Therapeutics, Inc. | Common stock, par value $0.001 per share | 0% | $0 | -$19,721,034 | 0 | -100% | Ridgeback Capital Investments L.P. | 30 Sep 2025 |
| AFMD | Affimed N.V. | Common shares | 0% | $0 | 0 | Ridgeback Capital Investments L.P. | 16 May 2025 | ||
| SMLR | Semler Scientific, Inc. | Common stock, par value $0.001 per share | 0% | $0 | -$29,283,360 | 0 | -100% | Ridgeback Capital Investments L.P. | 30 Sep 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|